Publicação
Pfizer company outlook: a "Covid-19 dependent" business?
| Resumo: | This equity report aims at analyzing and evaluating the pharmaceutical company Pfizer in a context of the global pandemic and the possible outcomes of the post-pandemic. We also researched the latest industry trends and analyzed the pharma regulation, M&A activity, patents, and emerging technologies. Thorough the report, we explained the methodologies and how recent industry and economic factors will affect the revenues of the main Pfizer’s pharmaceutical products |
|---|---|
| Autores principais: | Arias, David |
| Assunto: | Valuation Innovation R&D Healthcare Covid Vaccines Patents Oncology |
| Ano: | 2022 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| Resumo: | This equity report aims at analyzing and evaluating the pharmaceutical company Pfizer in a context of the global pandemic and the possible outcomes of the post-pandemic. We also researched the latest industry trends and analyzed the pharma regulation, M&A activity, patents, and emerging technologies. Thorough the report, we explained the methodologies and how recent industry and economic factors will affect the revenues of the main Pfizer’s pharmaceutical products |
|---|